Literature DB >> 1122683

Pharmacokinetics of procainamide intravenously and orally as conventional and slow-release tablets.

C Graffner, G Johnsson, J Sjögren.   

Abstract

Pharmacokinetics of procainamide were studied in healthy volunteers after single doses intravenously and orally as conventional and slow-release tablets and after repeated oral doses to steady state. The initial distribution after intravenous administration was rapid and the overall elimination in the beta-phase corresponded to t1/2 of 2.7 hr. The mean volume of the central compartment was small and only 4 percent of V-d (beta), which was 2.3 l/kg body weight. About 65 percent was excreted unchanged after intravenous administration and about 55 percent after a single oral dose of 500 mg. The recovery of the metabolite N-acetylprocainamide was 12 percent after both routes of administration. Procainamide was completely absorbed from the gastrointestinal tract and the first-pass elimination was very limited. The rates of absorption from the tablet compositions were well correlated to the in vitro dissolution properties. Administration of slow-release tablets every 8 hr gave about the same mean plasma level at steady state as ordinary tablets given every 4 hr, and the availability was the same from both preparations. The occasional high plasma concentration peaks after ordinary tablets were not observed after the slow-release tablets. Renal clearance was about 500 ml/min, indicating an active secretion in the tubules.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1122683     DOI: 10.1002/cpt1975174414

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Elimination rate of N-acetylprocainamide after a single intravenous dose of procainamide hydrochloride in man.

Authors:  C Graffner
Journal:  J Pharmacokinet Biopharm       Date:  1975-04

2.  Severe neutropenia consequent to sustained-release procainamide.

Authors:  M Mellino; J Hogan; H C Taylor
Journal:  Tex Heart Inst J       Date:  1983-03

3.  Acetylator phenotype and the clinical pharmacology of slow-release procainamide.

Authors:  W Campbell; W J Tilstone; D H Lawson; I Hutton; T D Lawrie
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

4.  Serum procainamide levels as therapeutic guides.

Authors:  J Koch-Weser
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

Review 5.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

6.  The pharmacokinetics of slow-release procainamide.

Authors:  W J Tilstone; D H Lawson; W Campbell; I Hutton; T D Lawrie
Journal:  Eur J Clin Pharmacol       Date:  1978-12-01       Impact factor: 2.953

7.  Comparison of the acetylation of procainamide and sulfadimidine in man.

Authors:  K Frislid; M Berg; V Hansteen; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

8.  A pharmacokinetic comparison of two sustained-release oral procainamide preparations.

Authors:  P Hore; P Bones; T Rollinson; H Ikram
Journal:  Br J Clin Pharmacol       Date:  1979-09       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of procainamide.

Authors:  E Karlsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

10.  Ethanol-induced increase in procainamide acetylation in man.

Authors:  H Olsen; J Mørland
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.